Advances in BAT physiology for understanding and translating into Pharmacotherapies for obesity and comorbidities

Abstract

With obesity growing in epidemic proportions and very few medical drugs that can be used for longterm there has been a need for some pharmacotherapy that can help maintain weight loss on longterm basis. Thus we made a PUBMED search for articles related to BAT metabolism in obesity using the MeSH terms, brown fat, beige, brite adipocytes, activation of BAT, cold induced activation, mechanism of action and found 1400 articles of which we selected 164 articles for this review. Duplicate articles were not included and those reviewed in our earlier articles were also not included. No meta analysis was also done. We identified different kinds of drugs capable of activating brown adipocyte (BAT) thermogenesis and classified them into 4 groups, with group 1 acting on beta3 adrenoceptors, group 2 on noradrenaline uptake, 3 on peroxisome proliferator-activated receptor (PPAR)–gamma which included mostly the thiazolidinedione group currently used for diabetes treatment of which pioglitazone is the most common one although not much studies have been done to study their action on BAT thermogenesis. Confirmation of BAT activation was done with use of 18–F–fluorodeoox glucose by PET/CT Studies. Of class 1 mirabegron offers most promise it is being used currently for overactive bladder. Many miscellaneous drugs like caffeine, nicotine, curcumin, capsaicin, forskolin, FGF21 have been considered as class4. Further role of BAT transplantation has been highlighted with very little BAT available for drug action to be of help in treating obesity.

Keywords: thermogenesis, brown adipocytes, 18F–FDG, mirabegron, pioglitazone, PPAR–gamma, curcumin, caffeine, nicotine, CB1 receptors

Introduction

According to the WHO more than 1 billion adults are overweight and of these at least 200million men and 300million women are clinically obese.1 In a prospective study where over 9million people were evaluated in the last 3 decades, it was found that the average body mass index (BMI) increased by 0.4–0.5kg/m²/decade and subregion trends showed that the average BMI increased by 1.4kg/m² in men and 1.9kg/m² in women/decade.2 Obesity has been found to be a major risk factor for many diseases like cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), stroke, hypertension and many cancers.3 Special emphasis has been laid on finding strategies by which energy expenditure can be increased ,with the discovery of brown and beige adipocytes in humans. Earlier we had summarized the location, differentiation, surface markers of brown adipose tissue (BAT) /Beige adipocytes and mechanisms other than cold/β3 adrenergic agonists by which they can be targeted to improve obesity and thus metabolic syndrome (MS) and other comorbidities.4,5 Here we further try to update how one can use enhancement of Brown adipose tissue (BAT) /Beige Brite adipocytes in the management of obesity and T2DM.

Methods

Thus we made a PUBMED search for articles related to BAT metabolism in obesity using the medical subject heading (MeSH) search terms, brown fat, beige, brite adipocytes, activation of BAT, cold induced activation, mechanism of action, treatment strategies with relevance to BAT.

Results

We found 1400articles of which we selected 164articles that were peer reviewed for this review from 1986 to 2018 .Duplicate articles were not included and those reviewed in our earlier articles were excluded. We examined all abstracts for relevant information about the pertinent topics. Additional literature was retrieved from references and cross references. No meta analysis was done.

Brown adipose tissue

Brown fat cells also have enzymes to synthesize and store triglycerides, although in BAT fat cells lipids are stored in multiple small fat droplets i.e they are multiloculated in contrast to white fat cells which are unilocular, containing one giant droplet of triglycerides. Besides BAT is composed of brown fat cells, along with plenty of blood vessels and nerves. In brown–type fat oxidative phosphorylation is uncoupled, so that the process of respiration is inefficient allowing for significant heat production (non shivering thermogenesis) through consumption of calories without ATP production, which is facilitated by up regulation of thermogenic promoting factors which includes uncoupling protein 1(UCP1).6 Typical brown adipocytes are present between the scapulae of rodents and in neck region of humans.8-10 Figure 1 Recently interest has emerged towards development of pharmacotherapies which try to augment brown adipose tissue (BAT) to raise energy expenditure following the accidental discovery and presence of BAT in adult humans as well besides their presence in smaller mammals and human infants, when on using 2–deoxo–2–Fluoro–D–Glucose (18F FDG) / positron emission tomography (PET) scanning in cancer patients several discrete areas of metabolically active BAT was suggested.11 Further recent data indicate that normal adult humans contain significant depots of UCP–1 positive brown fat which can be detected by 2–deoxo–2– Fluoro–D–Glucose (18F–FDG) / positron emission tomography (PET) / computed tomography (CT) scanning methods specially in supraclavicular and neck area (biopsy proven) (Figure 1).12-16

© 2018 Kaur et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.
Advances in BAT physiology for understanding and translating into Pharmacotherapies for obesity and comorbidities

---

**Positive transcriptional regulators**

Were Forkhead box C2 (FOXC2) and PR (PRD1‒BF‒RIZ1 homologous) domain containing 16 (PRDM16) although only PRDM 16 was supposed to determine brown cell fate in a cell autonomous manner.\(^{17,18}\)

**PR (PRD1‒BF‒RIZ1 homologous) domain containing 16 (PRDM16)**

Drives a fat differentiation programme. To understand the mechanism by which PRDM16 activates brown fat selective genes, chromatin immunoprecipitation (ChIP) followed by deep sequencing (ChIP seq) analysis in BAT revealed that PRDM16 binding is highly enriched at a broad set of brown fat selective genes. PRDM16 physically binds to MED1 a component of the Mediator complex and recruits it to superenhancers at brown fat selective genes. Deficiency in PRDM in BAT reduces MED1 binding at PRDM target sites and causes a fundamental change in chromatin architecture at key brown fat selective genes. Thus PRDM controls chromatin architecture and superenhancers activity in BAT. PRDM16 interacts with MED1 at brown fat specific genes to promote gene transcription. The binding of MED1 to PRDM16 appears to be direct since these factors are able to bind together in vitro as purified proteins. MED1 is a component of the Mediator complex which plays a key role in regulatory genes expression through a variety of mechanisms.\(^{19}\) Mediator bridges enhancer regions and associated transcription factor complexes with RNAII polymerase and the transcriptional machinery at the promoters.\(^{19}\) Harms et al suggest that PRDM16/PRDM3 binds to chromatin at enhancers, many of which are superenhancers (SE) in BAT selective genes via peroxisome proliferator activated receptor γ (PPARγ) and CCAAT/enhancer binding protein (C/EBP β) and likely other factors. At these sites PRDM16 recruits MED1/Mediator and by doing organizes higher order chromatin architecture and promotes

---

**Role of ewing sarcoma protein (EWS) / Y box protein 1 (YBX1) / bone morphogenetic protein7 (BMP7)**

Recently Park et al showed the role of multi domain protein Ewing sarcoma protein (EWS) which is a an RNA binding protein as a regulator of adipogenesis, upstream of BMP7. It acted in conjunction with Y box protein 1 (YBX1) to induce the transcriptional activation and production of BMP7 (Figure 2).\(^{24}\) Earlier Tseng et al had already shown that BMP7 is an important upstream regulator of PRDM 16 in brown preadipocytes.\(^{25}\) Importantly Ewing's null mutant BAT and beige preadipocytes ectopically expressed myogenic genes and the treatment of these with BMP7 could lead to a full rescue of brown adipogenic differentiation capacity. Further Park et al recommended to determine how this EWS/YBX1 expression activity is regulated to...
further elucidate brown fat lineage determination to plan treatment at an upstream level. Different studies have reported increased metabolic activity of BAT. Uptake of 2-deoxy-2-[18F]fluoro-D-glucose ([18F-FDG]), in human BAT positron emission tomography / computed tomography (PET/CT) studies. Simultaneously ways were found of examining BAT in rats with the use of [11C]-MBG, that is an analog of norepinephrine, followed by norepinephrine traspoters, which got visualized with the use of [11C]–Methyl reboxetine (MRB) and [11C]–[4-methylamino-4′-N, N-dimethyllarninoazobenzene (TAZA). Use of [11C]–acetate, [13C]–palmitate along with using radiolabelled fatty acids as metabolic substrates was done by other researchers. For getting newer strategies to be able to act regarding obesity therapy it is important to be able to measure the metabolic activity of BAT. Activity of BAT is indicated by the deposition of various metabolic substrates like [18F]-FDG, [11C]–acetate, [13C]–palmitate that is secondary to UCP1 activity, and stimulation of thermogenic function. This activated BAT might be used to develop strategies for fighting diabetes obesity besides hyperlipidemia. Imaging studies using [18F]-FDG PET/CT supports the biology of BAT in both humans along with animals. Increased [18F]-FDG uptake occurs in cold activated BAT both in humans (at16°C) as well as in rodents (−4°C). Previously for exploring BAT exposure to cold for long duration was the only way of studying BAT prior to PET, which was a function mediated by β-3 adrenergic system. The BAT amount varied from 30%–95%, that is much more than that found in retrospective studies.

**BAT activation induced by drugs**

Activating BAT at ambient temperature needs various pharmacological agents. Drugs used have been divided into 4 groups depending on their main site of action (Figure 3). Class 1 drugs represent the β-3 adrenergic receptor (AR) agonists that act on the β-3 AR, which are located on the adipocyte cell surface. Both in animal and human studies they have been used. Class 2 drugs are drugs which act by altering norepinephrine levels, either by directly mimicking norepinephrine effects or by blocking the effect of norepinephrine transporter (NET) which are located on the sympathetic nerve terminal. Class 3 drugs activate peroxisome proliferator activated receptor-γ (PPAR-γ) and activate within the adipocyte. Class 4 are drugs like natural products with limited information, that is growing now.

**Class 1 drugs**

Agonists for β-3AR at present are being used for overactive bladder (OAB). These β-3AR belong to the G-protein coupled receptors (GPCR) and are present in big quantities on brown adipocytes. Sympathetic nerves which contain norepinephrine innervate BAT, activate β-3AR. A lot of work has been used to examine these β-3AR by developing selective agonists for treatment of obesity. Cohen et al have recently reviewed how both brown and beige fat may be molecular parts of the same thermogenic machine. In both UCP1 dependent thermogenesis are required for the generation of heat in cells expressing lipids and carbohydrates by the leak of protons back across the inner membrane of the mitochondrial membrane by UCP1 (Figure 4). They further highlighted the importance of factors like early B cell factor 2 (Ebf2) up-stream of Prdm16 promoting binding of PPARγ to the promoters of BAT selective genes and role of euchromatic histone methyl transferase (EHMT1), histone methyl lysine transferase in the PRDM16 transcription factors complex which controls the adipose cell fate and loss of EHMT1 causes severe loss of brown fat characteristics, while inducing muscle differentiation in vivo. Similarly beige adipocytes also have selective factors upstream of PRDM 16, besides beige specific epigenetic regulators and modulators. TLE3 being a cofactor which belongs to the groucho family as a transcriptional integral of the PPAR γ and wingless and INT 1 proteins (Wnt) pathways. It competes with PRDM16 for binding to PPARγ and thus can modulate both white versus brown/beige phenotype. Over expression of transducer like enhancer of split3 (TLE3) can impair thermogenesis while deletion enhances thermogenesis in brown and beige fat.

**Figure 4** Courtesy ref no-89 Schematic adaptive thermogenesis in brown and beige adipocytes. This process is typically thought of as beige indirectly activated by cold via the sympathetic nervous system (SNS)catecholamine stimulated adrenergic receptors (BAR) ultimately activating UCP1-dependent thermogenesis. Adaptive thermogenesis can also be directly activated by cold in beige adipocytes and by other stimuli that may signal independently from the β-adrenergic receptors. The reducing equivalent generated by the tricarboxylic acid (TCA) cycle enter the ETC (electron transport chain). This generates a proton gradient across the inner mitochondrial membrane instead of linking this gradient to ATP synthesis via complex V. UCP1 is able to uncouple this gradient with the chemical energy to heat.

β-3AR selective agonists are derivatives of “2-hydroxy ethylamino” backbone which stimulates norepinephrine BRL37344, which is an active metabolite of BRL35135 has selective activity for adipocyte lipolytic response. 2-deoxy-[18F]-glucose is used to study glucose utilization index (GUI) of BRL35135. Treatment with BRL37344 chronically leads to a 34 fold rise in basal GUI of BAT, without any effect on GUI on other tissues. BRL35135 also improved glucose tolerance in genetically obese (ob/ob) and obese Zucker (fa/fa) rats at doses ineffective with anti obesity activity. Another β-3AR selective agonists is CL316,243 which is pharmacologically (RR)-5-[2,3, -(3chlor phenyl) –2-hydroxy-ethyl-amino[propyl]–1,3-
It is known that Norepinephrine stimulates β-3AR and that cold temperature might be increasing metabolism by raising Norepinephrine concentrations. It causes activation of cervical, parietic, intercostals and interscapular BAT(IBAT) as has been demonstrated by PET studies (Figure 2). Since this drug acts selectively, one can draw conclusions that increase in 18F-FDG uptake is secondary to stimulation of β-3AR, as has been seen with the actions of CL316,243 on overall energy expenditure in BAT. Its effects are raised in BAT mitochondrial multiplication along with energy expenditure, that is mainly affected by fast changes occurring in uncoupling protein 1(UCP1)intrinsic action that is secondary to sympathetic stimulation. When tried on humans the effects on energy expenditure following 8weeks of use of CL316,243 in young lean male subjects was no different from baseline. Thus use in humans was given up in view of its poor bioavailability. There are drugs which are similar structurally like mirabegron, rafabegron and solabegron that are being tried for use in overactive bladder (OAB) and irritable bowel syndrome (IBS). Rafabegron causes rise in energy expenditure, of the magnitude of 50kcal/day at highest dose in obese people, in both sexes. Effects of solabegron has not been studied for energy expenditure (EE) although it is being used for irritable bowel syndrome (IBS). Mirabegron, is being used for OAB, and is a β-3AR selective agonist. It activated ingual BAT (IBAT) metabolic activity, both in rat, along with in human, that was measured with the use of 18F-FDG PET/CT. Hence this rise in glucose metabolism in different species might be utilized for treatment of obesity along with T2DM. Talibegron or ZD 2079 and ZD 7114 belong to groups of drugs that have selective β-3AR activity and cause rise in EE by nonshivering along with decreased gain in weight, along with thermogenesis that is activated. Besides that ZD 7114 also has been found to have antagonist activity in these β-3AR’s in isolated rat ileum, causing no change in 24h EE in obese people although talibegron demonstrated some little stimulatory action on EE, thus it doesn’t offer much promise for Obesity/T2DM. Other β-3AR agonists which get used in clinical scenario are amibebron or SR58611A, that were used as antidepressants but were stopped. One finds expression of β-3AR in BAT, white adipose tissue (WAT), myocardium, skeletal muscle and liver. But, in brain expression of β-3 adrenoceptors was lower as compared to that in BAT. One can’t say if poor performance of amibebron is related to small concentrations of β-3AR or not.

**Class 2—drugs changing norepinephrine**

It is known that Norepinephrine stimulates β-3AR and that cold temperature might be increasing metabolism by raising Norepinephrine levels. Increasing the dosage of Norepinephrine caused an increase of 2-[3H]-DG (Glucose metabolic index) in BAT. This implies that norepinephrine raises the capability for BAT thermogenesis. Mice where UCP1 is ablated, adding norepinephrine to brown adipocytes lead to an increased oxygen consumption rate. Ephedrine has that structural similarity to norepinephrine, also increases BAT activity but only in lean and not obese patients. Comparing to placebo the BAT changes caused by ephedrine had a negative correlation with different body fat indices. Although chronic ephedrine therapy decreased body fat content, there was no association with a rise in BAT activity. But since there was decrease in BAT glucose disposal with the use of chronic ephedrine, it gave suggestion that this therapy reduced instead of increasing BAT activity. For the treatment of attention deficit hyperactivity disorder (ADHD), there is use of atomoxetine, that is a very efficacious and selective presynaptic NET blocker. Atomoxetine in lieu of rise in adrenergic neurotransmission causes raised synaptic concentrations of norepinephrine. Since a very selective NET ligand, 1C-MRB is taken up by BAT, there is suggestion that there are transporters present in BAT. Also 1C-TAZA via the NET in the BAT along with IBAT and other BAT regions also gets taken up as is shown by PET. Quantification of atomoxetine’s effects on BAT metabolism was done using 18F-FDG PET/CT recently. Much more increase occurs as compared to ephedrine. Since propranolol inhibited atomoxetine induced BAT activation to control levels, it suggests that action of atomoxetine is through β-3AR. Initial reports showed short term antidiobesity efficacy, causing modest short term weight loss in obese women. In case of binge eating disorders, atomoxetine was found to be useful in outdoor patients. But no weight lowering effect was seen in patients having gained weight with the use of clozapine or olanzapine. Another potent and selective inhibitor of NET uptake, i.e. nioxetine bound interscapular BAT brown adipose tissue (IBAT). Similarly binding of IBAT density from angiotensin an II infusion lead to good weight lowering effects, which was secondary to raised sympathetic transmission. Although sibutramine, which is also another NET reuptake inhibitor showed thermodinamic effects, it was removed from the market because of its CVS side effects. Treatment of fibromyalgia patients with another NET reuptake inhibitor, milnacapram showed roughly 5% weight loss in 3–6months.

**Class 3—PPARy activators**

Once PPAR γ is activated by thiazolidenediones, they affect both lipid along with carbohydrate metabolism by various mechanisms when used for treatment of T2DM. Since brown adipocytes increase energy expenditure, increase of brown fat adipogenesis could explain the good effects of these drugs in insulin sensitivity in humans. Rosiglitazone helps in proadipocyte cell line differentiation and helps in increasing IBAT mass. Once human preadipocytes were prepared from all depots that got rosiglitazone, there was an increase in UCP1 mRNA. Also troglitazone another thiazolidenediones was shown to increase IBAT in rodents who got treatment with troglitazone. But ciglitazone, although it caused reduction in blood glucose, triglycerides and food intake it did not change body weight in obese hyperglycemic mice. Though it did cause a reduction in blood sugar, currently it is not being used for T2DM treatment in any form of medication. GLUT4 expression gets increased by troglitazone in T2DM obese rat models and increases insulin sensitivity in non insulin dependent DM although with severe liver side effects. Currently pioglitazone is getting used to treat T2DM although it has some urinary bladder side effects in some cases. In a rat model it plays a role in remodeling of adipocytes. Balaglitazone decreased glucose levels without having any effect on fluid retention/bone formation in rats that were obese. It improved blood glucose levels along with HbA1c in diabetic patients. Another drug from this group raviglitazone decreased glucose levels by causing better insulin sensitivity in T2DM animals taking a small time. Clinical trials with raviglitazone are under way for T2DM therapy and assess what risks could be associated with this drug. Increase in BAT was caused by darglitazone, causing changes in morphology in rats. But development of darglitazone for use in clinical arena has been stopped. Hence of all the glitazones, pioglitazone is the most active, though it decreases blood sugars, whether it causes browning of adipocytes and helps in weight loss reduction has yet to be proved. There have not been any PET imaging studies for studying BAT activation in either animal or human models has been done. There is need to study whether in vivo BAT gets activated by using pioglitazone and that needs to be compared with class I drug miraberon.
Class 4 - natural [Products /other drugs]

Catecholamine release follows intra-peritoneal nicotine injection like norepinephrine that stimulates thermogenesis in BAT for energy expenditure.104 105 F- FDG uptake in BAT was increased by nicotine, an effect that got more increased by additional of ephedrine.41 Thus nicotine increases norepinephrine turnover along with BAT thermogenesis, and simultaneously increasing resting metabolic rate, all add to reduced obesity.106 Caffeine increased oxygen consumption in BAT mitochondria, and although increased BAT temperature it did not have that much effect on core temperature.107 Also adenosine receptors A2A also have been shown to take a part in BAT thermogenesis.108 Still it is not shown if there is interaction of adenosine receptors with caffeine is involved in BAT activity. Capsinoids or capsaicin has been known to reduce body fat. Energy expenditure (EE) increase caused by capsinoid is due to BAT involvement, as seen by studies in small rodents. Also 2 weeks of capsinoid treatment caused increased UCP1 expression.109 In humans also increase in energy expenditure (EE) occurs by activation of brown adipose tissue. Turmeric pigment curcumin has been studied for treatment of obesity related diseases. Its action is by acting directly with adipocytes, pancreatic cells, hepatic stellate cells, macrophages and muscle cells. It reverses insulin sensitivity, hyperglycemia, hyperlipidemia along with other obesity symptoms. Besides that it can bind to PPARγ by which it can stimulate human adipocyte differentiation.110 It also improves cold tolerance in mice along with expression of β3 adrenocorter gene in inginal WAT. Increase in norepinephrine levels was also observed with curcumin therapy.106 Forskolin induces thermogenic response in BAT.111 Adenylate cyclase enzyme gets activated directly by forskolin which further leads to increase in cyclic adenosine monophosphate (cAMP).112 This increased metabolism of BAT by forskolin in measurable by 18F- FDG PET/CT.113 Another drug rimonabant, a cannabinoid 1 (CB1) receptor drug lead to weight loss by causing increased BAT temperature by which it mediated weight loss through the peripheral endocannabinoid system, as proved by the use of peripheral CB1 receptor antagonist AM6545.114,115 Rimonabant got banned because of the suicidal side effects observed by its use.116 Still by using peripherally acting CB1 receptor drugs like AM6545 in PET imaging might help in further highlighting the role of this target receptor. A selective Kv1.3 peptide inhibitor ShK–186, shows marked effect in the treatment in a mouse model of diet induced obesity and insulinsensitivity.117 BAT activation is caused by ShK–186 is proven by increased glucose uptake, increased β-oxidation and raised transcription of UCP1 gene that is involved in BAT thermogenesis. ShK–186 decreased increase in weight even after voracious diet consumed in mice fed an obesity inducing diet. Increased membrane re-modelling along with simultaneous increase in PPARγ expression and metabolites which can cause activation of PPARγ might explain how this drug helps. As there is improvement in insulin sensitivity along with control of T2DM with PPARγ agonists,118 increased PPARγ signaling seen in mice receiving ShK–186 for treatment might be responsible for this peptides beneficial effects in treatment.

Potential of treatment

Class 1 drugs

Since in human BAT there is presence of β-3AR, it suggests therapeutic strategies can be used on this basis.119 Still there are problems with regard to selectivity and bioavailability of the drugs along with measurable weight loss with class drugs are not fully clear. CL316,243 possesses only 10 fold selectivity for human β-3 over β-2 adrenoceptor and also β-3AR mRNA is also seen in human heart,120 because of which one gets worried regarding the CVS side effects. Though with CL316,243,there are no changes in heart rate (HR), systolic and or diastolic blood pressure, no changes in ECG intervals have been seen nor any tremor development was observed.121 Although the newer drugs like mirabegron which also target this receptor have the food and drug administration(FDA) approval for OAB, still it is not clear what is their role in treating T2DM.122 Use of CL316,243 chronically has been shown to effect obesity in mice and rats.13,14,15 Also acute β-3AR stimulation with the use of CL316,243 increases BAT metabolism in vivo which is measurable quantitatively with 18F- FDG PET/CT by observing 18F-FDGP uptake in rats. Once exposed to cold temperature, In early phase, there is mobilization of fatty acids from WAT, that is known to be the initial source for activation of BAT instead of breakdown of fat depots stored in BAT.116 On histology the number of lipid vacuoles in BAT was significantly reduced following stimulation with CL316,243 though no change in WAT lipid content was seen between the 2 situations.124 Thus during acute administration of CL316,243,glucose metabolism along with stored lipids lipolysis in BAT are the initial ways by which there is activation of tissue instead of mobilization of fatty acids from WAT. Despite similar binding of β3AR in humans as well as rodent receptor in vitro, in human β3AR it just remains as partial i.e 60% agonist, in contrast to it being a full agonist, having a poor bioavailability, only 10% of it getting absorbed orally.46 In Zucker lean (ZL) and Zucker obese (ZF) rats the difference in β3 adrenocorter agonist mediated activation of BAT was investigated with the use of 18F-FDG PET/CT. Brain 18F-FDG PET studies had been used in ZF model to study the leptin receptor deficiency centrally.116,117 There was a 4 fold BAT activation in ZL in comparison to 2 fold in ZF rats as compared to saline.118 This reduced activation goes parallel with the lower β3 adrenoceptor levels in ZF rats. Although there were lower β3 adrenoceptor levels along with decreased G-protein coupling in ZF rat model ,measurable effect of CL316,243 was seen on BAT. Considerably lower opacity was seen in ZF in contrast to ZL as seen by CT, which suggests that there is low abundance of brown adipocytes in the IBAT region. Further attempt is being done for developing treatment strategies where leptin receptor function is restored regarding human obesity therapeutics.121 Conservation of residual β3AR is seen in the leptin deficient fa/fa rat model, which is functional with respect to enhancing metabolic activity. Along with that there is decreased coupling of β3AR with the G protein in white adipocytes.122 Other pointers which impair BAT thermogenesis are abnormalities in central metabolism regulation and neuroendocrine metabolism.123 Studying chronic β3AR drug treatment in this rat model might help in restoration of brown adipocytes. streptozotocin treated rat model is used to study type1 diabetes mellitus (T1DM), and lower metabolic capacity of IBAT is seen in this model.124 Baranwal et al further verified the loss of metabolic capacity of BAT in streptozotocin diabetic rats.125 Thus difference in the 2 diabetic models is that the decrease in IBAT activity in the Zucker fat rat might occur secondary to impaired β3AR signaling while the decrease that is seen in streptozotocin diabetic rats impairment might be driven by mitochondrial dysfunction. They further suggested that stimulation of β3AR activates IBAT in this T1DM rat model and can increase metabolic activity. But trying to change norepinephrine levels with the use of atomoxetine did not have much effect, possibly because of impaired norepinephrine turnover .If insulin receptors are blocked in BAT streptozocin –treated mice,
it caused impaired glucose tolerance just as that seen in nondiabetic animals which suggested the importance of insulin receptor activity in helping reverse DM.123 Mirabegron, which is a selective β adrenergic agonist ,is used to treat overactive bladder in a dose of 200mg. This drug has received clinical approval and has been shown to activate human brown adipocytes that might rewire interest in this pathway.87 In contrast to CL316,243,Merabegron has a much better agonist potency as far as humans are concerned.16,64 Another selective β3AR agonist is amibebron which crosses blood brain barrier (BBB),having antidepressant like properties,like its ability to increase serotonin synthesis.17 So more studies are required to study disease models using these newer human β3AR drugs.

Class 2 drugs

A selective norepinephrine reuptake inhibitor is atomoxetine, that has low abuse potential.27 Structurally it is similar to the antidepressant floxetine, and acts by increasing synaptic norepinephrine levels,126,127 having few side effects(CVS side effects rate (3%)and raised blood pressure.128,129 It is already being used to treat ADHD in psychiatry, both pediatric and adult with very little adverse effects.10,111 When fasting there was excessive 18F–FDG increase in BAT caused by atomoxetine as compared to control.121 In patients with pheochromocytoma, where there is increased release of epinephrine along with norepinephrine from the adrenal gland, there is intense 18F–FDG uptake.132,133 Because of intense adrenergic interaction with β1 and β2 adrenoceptors, there are serious CVS side effects seen in these patients.134 Hence specificity for β3AR is required for developing agents for BAT activation.

Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor that had been earlier used for obesity therapy because it decreased appetite along with initiating weight loss along with diet and exercise. It improved insulin sensitivity along with glucose metabolism. All these effects were caused by intrinsic effects of the drug rather than weight loss, but it was withdrawn from market because of CVS side effects.135 Another norepinephrine and serotonin reuptake inhibitor antidepressant is milnacipran, that has been used in comorbid depression that is common in T2DM patients.136 Improvement of blood glucose and Hb A1c levels occur in T2DM patients. Because of relief of depression, better self care occurs causing improved metabolic parameters,136 with BAT activation protecting from hyperglycemia.137

Class 3 drugs

Because of serious side effects many thiazolidinediones have been given up for BAT activation.13,80 Currently pioglitazone is the one PPAR gamma activator used for T2DM.138 In a recent study India specific algorithm for management of T2DM using pioglitazone was done.139 Still role of BAT has not been demonstrated in glucose lowering effect of pioglitazone, as UCP1 in human epicardial adipose tissue did not change.140 Thus measuring effect of pioglitazone on 18F–FDG uptake using this imaging method might help to be able to confirm its metabolic activity.

Class 4 drugs

Nicotine ,though activates BAT,141 its weight lowering effect seen with smoking is secondary to its hypothalamic actions.142 Forskolin activates cyclic AMP via adenylyl cyclase activation in multiple cell types.143 Forskolin although activated BAT its action on heart myocardium along with adverse effects like headache, decreased BP, increased HR, with limited weight lowering effects don’t make it a good choice. Caffeine has small effects regarding increasing fat metabolism that gets accentuated with use with ephedrine.144 Capsaicin may have role in obesity through brown and beige adipocytes.145,146 Curcumin promotes browning of WAT.147 A bioavailable form of curcumin increased weight loss in overweight people having metabolic syndrome (MS).148 Besides rimonabant, which has side effects, other peripheral CB1 selective drugs might be useful.149,150 ShK186,is undergoing trials for therapy in autoimmune diseases.151 It had great effects in a mouse model of diet induced obesity.152 Fibroblast growth factor 21(FGF21) is being targeted for obesity and may partially activate BAT.152,153

BATH transplantation

Transplantation of BAT might have edge over pharmacological drugs as BAT levels are quiet low in obese people. Recent reviews cover the advantages of this in improving body composition and metabolism.149 Stem cells for developing AT implants are being explored to overcome problems related to availability of these implants for providing BAT for human therapy purpose.153,154 Thus one can combine these with pharmacologic approaches.

Discussion and conclusion

Thus we have reviewed in detail the BAT physiology, its positive transcriptional regulators like FOXC2, PRDM 16, the upstream regulators of PRDM16 like EWS/YYX1 and BMP7and importance of understanding in formulating treatment strategies. The various drugs that might help have been divided into 4 classes, with class1 drugs being the beta 3 adrenergic receptor agonists located on the adipocyte cellsurface, class 2 drugs acting by changing norepinephrine levels,acting directly or mimicking norepinephrine effects or by blocking norepinephrine transporter, that are located on the sympathetic nerve terminal, class 3 drugs acting on PPAR –gamma and class 4 being miscellaneous. Since presence of BAT in adults is low,155-161 there is problem in utilizing it for changing metabolism. BAT gets activated only once need for thermogenesis is there or it is activated pharmacologically.24,27 In view of its effects potentially,162,153 pharmacological stimulation attempts have increased.162,163 Engineered tissue transplantation along with pharmacologically induced brown adipocyte biogenesis is available now and may pave the development of therapies for obesity and T2DM. Of class1 drugs mirabegron offers great clinical promise, with further clinical trials on it effects on EE and thus weight lowering effect is needed. Of type2 drugs although sibutramine has been withdrawn from the market, atomoxetine is a drug that can be further studied for its effects on EE and thus obesity. Pioglitazone is the drug that is currently being used clinically for treating diabetes mellitus, although its role on EE,BAT metabolism and thus weight loss needs to be studied. Of the class4 drugs curcumin, nicotine, peripheral CB1 drugs need to be further studied for developing as antiobesity targets. Finally BAT transplantation might prove to be more effective than pharmacological agents alone, or might help in combination with them to improve BAT metabolism and thus EE and obesity.

Acknowledgements

None.

Citation: Kaur KK,Allahbadia G, Singh M, et al. Advances in BAT physiology for understanding and translating into Pharmacotherapies for obesity and comorbidities. MOJ Drug Des Develop Ther. 2018;2(5):166–176. DOI: 10.15406/mojddt.2018.02.00057
Conflict of interests

The Author declares that there is no conflict of interest.

References

1. WHO Obesity and overweight. USA; 2013.

2. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional and global trends in body mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country–years and 9.1 million participants. Lancet. 2011;377(9765):557–567.

3. Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance. Physiol Rev. 2004;84(1):277–359.

4. Kocher Kaur Kulvinder, Allahbadia GN, Singh M. An Update on a Etiopathogenesis and Management of Obesity. Obes Control Ther. 2016;3(1):1–17.

5. Kocher Kaur Kulvinder, Allahbadia GN, Singh M. Therapeutic applications of the Recent Understanding of ‘‘Brown and Beige ‘’ Adipocyte Physiology. Adv Tech Biol Med. 2015;3:128.

6. Kocher KK, Allahbadia GN, Singh M. An Update on Micro RNA’s and Metabolic Regulation with Future Potentials Regarding Diagnosis and treatment of Obesity, Metabolic Syndrome and other related Disorders. J Health Med Informat. 2015;6(2):100184.

7. Bray GA, Bellinger T. Epidemiology, trends and morbidities in obesity and the metabolic syndrome. Endocrine. 2006;29:109–117.

8. Cinti S. The adipose organ. Prostaglandin Leukot Essent Fatty Acids. USA. 2006;73:9–15.

9. Lidell ME, Betz MJ, Leinhard OD, et al. Evidence for two types of brown adipose tissue in humans. Nat Med. 2013;19:631–634.

10. Cypess AM, White AP, Vernochan C, et al. Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. Nat Med. 2013;19:635–639.

11. Nedergaard J, Bergtsson T, Cannon B. Unexpected evidence for active brown adipose tissuein adult humans. Am J Physiol Endocrinol Metab. 2007;293:444–452.

12. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509–1517.

13. Marken Lichtenbelt WD, Vanhoomrig JW, Smulders NM, et al. Cold activated brown adipose tissue in healthy men. N Engl J Med. 2009;360(15):1500–1508.

14. Virtanen KA, Iciddel ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518–1525.

15. Orava J, Nuutila P, Lidell ME, et al. Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell Metab. 2011;14(2):272–279.

16. Mirbolooki MR, Constantinescu CC, Pan ML, et al. Quantitative assessment of brown adipose tissue metabolic activation and volume using 18F–FDG/PET/CT and beta–3 adrenergic receptor activation. EJNMMI Res. 2011;1:10.

17. Cederberg A, Gronning LM, Ahren B, et al. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia and diet induced insulin resistance. Cell. 2001;106(5):563–573.

18. Seale P, Kajimura S, Yang W, et al. Transcriptional control of brown fat determination by PRDM16. Cell Metab. 2007;6(1):38–54.

19. Chen W, Roeder RG. Mediator dependent nuclear receptor function. Semin Cell Dev Biol. 2011;22(7):759–768.

20. Harms MJ, Lim HW, Ho Y, et al. PRDM 16 binds MED and controls chromatin architecture to determine a brown fat transcriptional program. Genes Dev. 2015;29(3):298–307.

21. Lida S, Chen W, Nakaidai T, et al. PRDM16 enhances nuclear receptor– dependent transcription of brown fat–specific Ucp1 gene through interactions with Mediator subunit MED1. Genes Dev. 2015;29(3):308–324.

22. Seale P. Transcriptional Regulatory circuits Controlling Brown fat Development and Activation. Diabetics. 2015;64(7):2369–2375.

23. De Sousa M, Porras DM, Perry CGR, et al. p107 is a crucial regulator for determining the adipocyte lineage fate choices in stem cells. Stem Cells. 2014;32(5):1323–1336.

24. Park HJ, Kang JH, Lee SI, et al. Amulifunctional protein EWS is essential for early brown fat lineage determination. Dev Cell. 2014;26(4):393–404.

25. Tseng YH, Kokkotu E, Chultz TJ, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature. 2008;454(7207):1000–1004.

26. Han YF, Gharehpagh E, Kamel EM, et al. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med. 2003;29(10):1393–1398.

27. Cohade C, Osman M, Pannu HK, et al. Uptake in supraclavicular area fat (USA-Fat)description on 18F–FDG PET/CT. J Nucl Med. 2003;44(2):170–176.

28. Tuong MT, Erasmus JJ, Munden RF, et al. Focal FDG uptake in mediastinial brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. Amer J Radiol. 2004;183(4):1127–1132.

29. Okayuma C, Sakane N, Yoshida T, et al. 1231–or 1251–Metaiodobenzyl guanidine visualization of brown adipose tissue. J Nucl Med. 2002;43(9):1234–1240.

30. Lin SF, Fan X, Yeckel CW, et al. Ex–vivo and in vivo evaluation of the Norepinephrine transporter ligand [(11)C]MRB for Brown adipose tissue imaging. Nucl Med Biol. 2012;39(7):1081–1086.

31. Pan ML, Mukherjee MT, Patel HH, et al. Evaluation of [(11)C]TAZa for amyloid A β plaque imaging in postmortem Alzheimers diseasebrain regions and whole body distribution in rodent PET/CT. Synapse. 2016;70(4):163–176.

32. Nemianich S, Rani S, Shoghi K. In vivo multi–tissue efficacy of peroxisome proliferator–activated receptor–γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats. Obesity. 2013;21(12):2522–2529.

33. Labbe SM, Caron A, Bakan I, et al. In vivo measurement of energy substrate contribution to cold induced Brown adipose tissue thermogenesis. FASEB J. 2015;29(7):1357–1359.

34. Inokuma K, Ogura–Okamatsuyama T, Toda C, et al. Uncoupling protein 1 is necessary for nor epinephrine induced glucose utilization in brown adipose tissue. Diabetes. 2005;54(5):1385–1391.

35. Rakelt A, Haren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol. 2014;10(1):24–36.

36. Van Markel Lichtenbelt WD, Vanhoomrig JW, Smulders NM, et al. Cold activated brown adipose tissue. In healthy men. N Engl J Med. 2009;360:1500–1508.

37. Baba S, Jacene HA, Engles JM, et al. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010;51(2):246–250.
Advances in BAT physiology for understanding and translating into Pharmacotherapies for obesity and comorbidities

J Biol Chem.

Citation:

58. 57. 56. 55. 54. 53. 52. 51. 48. 44. 43. 42. 38. 37. 36. 35. 34. 33. 32. 31. 30. 29. 28. 27. 26. 25. 24. 23. 22. 21. 20. 19. 18. 17. 16. 15. 14. 13. 12. 11. 10. 9. 8. 7. 6. 5. 4. 3. 2. 1.

1.街头 T, Sakane N, Wakabayashi Y et al. Anti-Obesity effects of CL–316, 243, a highly specific β–3 adrenergic receptor agonist in yellow KK mice. Life Sci. 1994;54(7):491–498.

3. Whistle A, Relat Parto J, Vidal Puig A. Pharmacologic strategies for targeting BAT thermogenesis. Trends Pharm. Sci. 2013;34:347–355.

5. Michael MC, Korstanje C. β–3 adrenoceptors agonists for overactive bladder syndrome. Role of transcriptional pharmacology in a repositioning clinical drug project. Pharm. Therapeutics. 2016;159:68–82.

7. Ursino MG, Vanina A, Laschke M, et al. The β3 adrenoceptor agonist on neuroendocrine mechanism controlling energy balance. J Clin Endocrinol Metab. 2007;92(2):527–531.

9. Bianchetti A, Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical β-3 adrenoceptors in rat colon. Br J Pharm. 1995;104(4):831–839.

11. Sumners RJ, Pappaoiamou H, Harris S, et al. Expression of a typical β3-adrenoceptor in rat ileal ileum. Br J Pharm. 1993;110(4):1375–1380.

13. van Oortmerssen G, Horta O, et al. β3-adrenoceptors in morbidly obese subjects. PLoS one. 2011;6:e17247.

15. Matthias A, Kerstien BE, Ohlson J, et al. Responses in brown fat cells are fully UCP1–dependent UCP2 or UCP3 cannot substitute for UCP1 in adrenergically or fatty acid induced thermogenesis. J Biol Chem. 2000;275(33):25073–25081.

17. Carey AL, Formosa MF, Van Every B, et al. Ephedrine activates Brown adipose tissue in lean but not obese humans. Diabetologia. 2015;58(1):147–155.
78. Carey AL, Pajtak R, Formosa MF, et al. Chronic ephedrine administration decreases brown adipose tissue activity in a randomized controlled human trial: implications for obesity. *Diabetologia*. 2015;58(5):1045–1054.

79. Garnock-Jones KP, Keating GM. Adiponectin: a review of its use in attention deficit/hyperactivity disorder I children and adolescents. *Pediatr Drugs*. 2009;11(3):203–226.

80. Bymaster FP, Katner JS, Nelson DL, et al. Adiponectin increases extracellular levels of norepinephrine and dopamine prefrontal cortex of rats: a potential mechanism for efficacy of attention deficit/hyperactivity disorder. *Neuropharmacology*. 2002;7(5):699–711.

81. Mirbolouki MR, Constantinescu CC, Pan ML, et al. Targeting presynaptic norepinephrine transporter in brown adipose tissue: Axonel imaging approach and potential treatment for diabetes and obesity. *Synapse*. 2013;67(2):79–93.

82. Gadde KM, Yonish GM, Wagner HR, et al. Adiponectin for weight reduction in obese women: a preliminary randomized controlled trial. *Int J Obes*. 2006;30(7):1138–1142.

83. Mc Elroy SL, Gurtdjikova A, Kotwal R, et al. Adiponectin in the treatment of binge eating disorder: randomized placebo controlled trial. *J Clin Psych*. 2007;68(3):390–398.

84. Ball MP, Warren KR, Feldman S, et al. Placebo controlled trial of Adiponectin for weight reduction in people with obesity hyperfunction treated with clobazapine or olanzapine. *Clin Schizophr Relat Psychoses*. 2011;5(1):17–25.

85. King VL, Dwoskin LP, Classis LA. Cold exposure regulates the norepinephrine uptake transporter rat brown adipose tissue. *Am J Physiol*. 1999;276(2):143–151.

86. King VL, Dwoskin LP, Bharadwaj K, et al. Angiotensin II stimulates sympathetic neurotransmission to adipose tissue. *Physiol REP*. 2013;1(2):e00014.

87. James WP, Caterson JD, Coutinho W, et al. Effect of sibutramine on cardiovascular out comes in overweight and obese subjects. *N Engl J Med*. 2010;363(10):905–917.

88. Arnold LM, Palmer RH, Hufford MR, et al. Effect of minacepram on body weight in patients with fibromyalgia. *Int J Gen Med*. 2012;5:879–887.

89. Salmone S. Plerotropic effects of glaziones: double edge sword. *Front Pharm*. 2011;2:1–6.

90. Digby JE, Mentage CT, Sewler CP, et al. Thiazolidinediones exposure increases the expression of uncoupling protein 1i cultured human preadipocytes. *Diabetes*. 1998;47(1):138–141.

91. Breider MA, Gough AW, Haskins JR, et al. Troglitazone induced heart and adipose tissue cell proliferation in mice. *Toxicol Pathol*. 1999;27(5):545–552.

92. Chang AY, Wyse BM, Gilchrist BJ, et al. Ciglitazone, a new hypoglycaemic agent. *Studies in ob/ob and db/db mice diabetic Chinese hamsters and normal and streptozotocin diabetic rats. Diabetes*. 1983;32(9):830–838.

93. Yamamoto Y, Nakajima M, Yamazaki H, et al. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. *Life Sci*. 2001;70(4):471–482.

94. Henriksen K, Byrjaens I, Nielsen RH, et al. A comparison of glycaemic control, water retention and muscleoskeletal effects of balaglitazone and pioglitazonein diet induced obese mice. *Eur J Pharmacol*. 2009;616(3):140–145.

95. Henriksen K, Byrjaens I, Qvist P, et al. BALLET Trial Investigators. Efficacy and safety of of the PPAR–gamma partial agonist balaglitazone and pioglitazone and placebo: a phase III, randomized parallel group study in patients with type2 diabetes on stable insulin therapy. *Diabetes Metab Res Rev*. 2011;27(4):392–401.

96. Kanda S, Nakashima R, Takahashi K, et al. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator activated receptor–gamma agonist in obese diabetic rodent models. *J Pharm Sci*. 2009;111(2):155–166.

97. Koffarnus RL, Wargo KA, Philippe HM. Rivoglitazone: A new thiazolidinedione for the treatment of type2 diabetes mellitus. *Ann Pharmacother*. 2013;47(6):877–885.

98. Aleo MD, Lundeen GR, Blackwell DK, et al. Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator activated receptor–gamma agonist. *J Exp Ther*. 2003;305(3):1173–1182.

99. Mano–Ottagiri A, Iwasaki–Sekino A, Ohata H, et al. Rosiglitazone suppresses energy storage through activation of sympathetic outflow to brown adipose tissue via corticotrophin releasing factor type1 receptor. *Neurosci Lett*. 2009;455(1):26–29.

100. Yoshida T, Yoshida K, Hiraoka N, et al. Effect of rosiglitazone on peroxisminturn over and and thermogenesis in brown adipose tissue and metabolic rate in MS obse mice. *J Nutr Sci Vitaminol (Tokyo)*. 1990;36(2):123–130.

101. Yoshida T, Yoshida K, Karmara K, et al. Caffeine activates brown adipose tissue thermogenesis and metabolic rate in mice. *J Nutr Sci Vitaminol (Tokyo)*. 1990;36(2):173–178.

102. Gnad T, Scheber S, Kugeliv IV, et al. Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptor. *Nature*. 2014;516(7531):395–399.

103. Yonishiro T, Aita S, Kawai Y, et al. Nonpunpang capsinoids increase energy expenditure through the activation of brown adipose tissue in humans. *Am J Clin Nutr*. 2012;95(4):845–850.

104. Aggarwal BB. Targeting inflammation induced obesity and metabolic diseases by Curcumin and other nutraceuticals. *Ann Rev Nutr*. 2010;30:173–190.

105. Wang S, Wang X, Zichen Y, et al. Curcumin promotes browning of white adipose tissue in a norepinephrine dependent way. *Biochem Biophys Res Commun*. 2015;466(2):247–253.

106. De Jesus LA, Carvalho SD, Riberio MO, et al. The type2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. *J Clin Invest*. 2001;108(9):1379–1385.

107. Verty ANA, Allen AM, Oldfield BJ. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. *Obesity*. 2009;17(2):254–261.

108. Boon MR, Kooijman S, Van Dam AD, et al. Peripheral cannabinoid receptor blockade activates brown adipose tissue and recruits beige adipocytes via A2A receptor. *Nature*. 2014;516(7531):395–399.

109. Moreira FA, Crippa JA. The psychiatric side effects of rimonabant. *Rev Bras Psiquiatr*. 2009;31(2):145–153.

110. Upadhyay SK, Eckel–Mahan KL, Mirbolouki MR, et al. Selective Kv1.3 channel blockers therapeutic for obesity and insulin resistance. *Proc Natl Acad Sci*. 2013;110(4):2239–2248.

111. Wilding JP. PPAR agonists for the treatment of cardiovascular diseases in patients with diabetes. *Diabetes Obes Metab*. 2012;14(11):973–982.

112. Michael MC, Harding SE, Bond RA. Are there functional beta (3) adrenoceptor in the human heart? *Br J Pharmacol*. 2011;162(4):817–822.

113. DeSouza CJ, Hirshman MF, Horton ES. CL316, 243, a beta 3-specific adrenoceptor agonist, enhances insuln–stimulated glucose disposal in nonobese rats. *Diabetes*. 1997;46(8):1257–1263.

114. Park JW, Jung KH, Lee JH, et al. 18F–FDG PET/CT monitoring of beta3
agonist-diminished brown adipose tissue in white adipose tissue. *J Nucl Med.* 2015;56(1):153–158.

115. Baba S, Engles JM, Huso DL, et al. Comparison of uptake of multiple clinical radionuclides into brown adipose tissue under cold stimulated and non-stimulated conditions. *J Nucl Med.* 2007;48(10):1715–1723.

116. Deitulius JA, Liu LF, Belury MA, et al. Beta 3 adrenergic signaling acutely down regulates adipose triglyceride lipase in brown adipocytes. *Lipids.* 2010;45(6):479–489.

117. Virtanen KA, Haaparanta M, Gronroos T, et al. 2-[18F] fluoro-2-deoxy-D-glucose combined with microdialysis can be used for the comparison of tissue metabolism in obese and lean rats. *Diabetes Obes Metab.* 2002;4:60–68.

118. Listro D, Guiducci L, Burchelli S, et al. Brain glucose overexposure and lack of acute metabolic flexibility in obese and type 2 diabetes: a PET-[18F]FDG study in Zucker and ZDF rats. *J Cereb Blood Flow Metab.* 2010;30(5):895–899.

119. Schade KN, Baranwal A, Liang C, et al. Preliminary evaluation of 3-adrenoceptor agonist-induced 18 F-FDG metabolic activity in brown adipose tissue of obese Zucker rat. *Nucl Med Biol.* 2015;42(8):691–694.

120. Roujeau C, Jockers R, Dam J. New pharmacological perspectives for the leptin receptor in the treatment of obesity. *Front Endocrinol (Lausanne).* 2014;5:167.

121. Mory G, Wiel M, Adli H, et al. Impaired beta-adrenergic signaling pathway in white adipocytes of suckling fat/fat Zucker rat: a defect of receptor coupling. *Int J Obes Relat Metab Disord.* 2001;25:1592–1598.

122. Levin BE, Finnegan MB, Marquet E, et al. Defective brown adipose oxygen consumption in obese Zucker rats. *Am J Physiol.* 1984;247(1):E94–E100.

123. Seydoux J, Chinet A, Schneider-Picard G, et al. Brown adipose tissue metabolism in streptozotocin-diabetic rats. *J Endocrinol.* 1983;113(2):604–610.

124. Baranwal A, Mirbolooki MR, Mukheerjee J. Initial assessment of brown adipose tissue activity in streptozotocin induced type 1 diabetes rodent model using 18F-FDG PET/CT. *Mol Imag.* 2015;14(12):22–33.

125. Gunawardana SC, Piston DW. Reversal of type 1 diabetes in mice by Brown adipose tissue transplant. *Diabetes.* 2012;61(3):674–682.

126. Scherer D, Hassel D, Bloebs R, et al. Selective noradrenergic upturn inhibit atomoxetine directly blocks HERG currents. *Br J Pharmacol.* 2009;158(2):226–236.

127. Ledbetter M. Atomoxetine: A novel treatment for child and adult ADHD. *Neuropsychiatr Dis Treat.* 2006;2(4):455–466.

128. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of severe cardiovascular events in young and middle aged adults. *JAMA.* 2011;306(24):2673–2683.

129. Adler LA, Spencer TJ, Milton DR, et al. Long term, open label study of the safety and efficacy of Atomoxetine in adults with attention-deficit/hyperactivity disorder in interim analysis. *J Clin Psychiatry.* 2005;66(3):294–299.

130. Michelson D, Adler LA, Spencer TJ, et al. Atomoxetine in adults with ADHD: two randomized, placebo controlled studies. *Biol Psychiatr.* 2010;11:684–688.

131. Rosler M, Casas M, Konofal E, et al. Attention–deficit/hyperactivity disorder in adults. *World J Biol Psychiatry.* 2010;11(5):684–688.

132. Iyer RB, GuoCC, Perrier N. Adrenal pheochromocytoma with surrounding brown fat stimulation. *AJR.* 2009;192(1):100–101.

133. Yamaga LY, Thorn LF, Wagner J, et al. The effects of catecholamines on the glucose uptake in Brown adipose tissue demonstrated by 18F–FDG PET/CT in a patient with adrenal pheochromocytoma. *Eur J Nucl Med Mol.* 2008;35(2):446–447.

134. Zelinka T, Petrak R, Turkova H, et al. High incidence of cardiovascular complications in pheochromocytoma. *Eur J Nuc Med Mol.* 2008;35:446–447.

135. Scheen AJ. Cardiovascular risk benefit profile of sibutramine. *Am J Cardiovasc Drugs.* 2010;10(5):321–324.

136. Abrahamian H, Hofmann P, Prager R, et al. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). *Neuropsych Dis Treat.* 2009;5:261–266.

137. Bartelt A, Bruns OT, Reimer R, et al. Brown adipose tissue activity controls triglyceride clearance. *Nat Med.* 2011;17(2):200–205.

138. Scherthanner G, Cuirrie CJ, Scherthanner GH. Do we still need plogilizone for the treatment of type2 diabetes? A risk benefit critique in 2013. *Diabetes Care.* 2013;36(Suppl 2):S155–S161.

139. A proposed India specific algorithm for management of type2 diabetes. *Diabetes Tech Ther.* 2016;18(6):346–350.

140. Sacks HS, Fain JN, Holman B, et al. Uncoupling protein–1related messenger ribonucleic acids in human epicardial and other adipose tissues: Epicardial fat functioning as brown fat. *L Clin Endocrinol Metab.* 2009;94(9):3611–3615.

141. Wellman PJ, Marmon MM, Reich S, et al. Effects of nicotine on body weight food intake and Brown adipose tissue thermogenesis. *Pharm Biochem Behav.* 1986;24(6):1605–1609.

142. Martinez de Morentin PB, Whittle AJ, Ferno J, et al. Nicotine induces negative energy balance through hypothalamic AMP activated protein kinase. *Diabetes.* 2012;61(4):807–817.

143. Insel PA, Ostoemn LS. Forskolin as a tool for examining adenylyl cyclase expression, regulation and G protein signaling. *Cell Mol Neurobiol.* 2003;23(3):305–314.

144. Jeukendrep AE, Randell R. Fat burners, nutrition supplements that increase fat metabolism. *Obes Rev.* 2011;12(10):841–851.

145. Ohyama K, Nogusa Y, Shinoda K, et al. A synergistic anti-obesity effect by a combination of capsinoids and cold temperature through promoting beige adipocytes biogenesis. *Diabetes.* 2016;65(5):1410–1423.

146. Kida R, Yoshida H, Murakami M, et al. Direct action of capsinin in brown adipogenesis and activation of brown adipocytes. *Cell Biochem Funct.* 2016;34(1):34–41.

147. Wang S, Wang X, Ye Z, et al. Curcumin promotes browning of white adipose tissue in a norepinephrine dependent way. *Biochem Biophys Res Commun.* 2015;466(2):247–253.

148. Di Pierro F, Bressan A, Ranaldi D, et al. A potential role of bioavailable Curcumin in weight loss and omental adipose tissue decreases preliminary data of a randomized, controlled triall overweight people with metabolic syndrome. Preliminary study. *Eur Rev Med Pharm Sci.* 2015;19(21):4195–4202.

149. Addy C, Wright H, Van Laere K, et al. The acetyl CB1R inverse agonist tramabate mediates weight loss by increasing energy expenditure and decreasing calorie intake. *Cell Metab.* 2008;7(1):768–778.

150. Gadde KM, Allison DB. Cannabinoid–1 Receptor antagonist Rimon abant, for management of obesity and related risks. *Circulation.* 2006;114:974–984.

151. Chi Y, Pennington MW, Norton RS, et al. Development of a sea anemone for management of obesity and related risks. *Circulation.* 2006;114:974–984.
153. So WY, Leung PS. Fibroblast growth factor 21 as an emerging therapeutic target for type 2 diabetes. *Med Res Rev.* 2016;36(4):672–704.

154. Stanford KL, Middlebeek RJW, Townsend KL, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. *J Clin Invest.* 2013;123(1):215–223.

155. Tharp KM, Stahl A. Bioengineering beige adipose tissue therapeutics. *Front Endocrinol.* 2015;6:164.

156. Roman S, Agil A, Peran M, et al. Brown adipose tissue and novel therapeutic approaches to treat metabolic disorders. *Translat Res.* 2015;165(4):464–479.

157. Nedergaard J, Børglum T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. *Am J Physiol Endocrinol Metab.* 2007;293(2):444–452.

158. Au Yong IT, Thorn N, Ganatra R, et al. Brown adipose tissue and seasonal variation in humans. *Diabetes.* 2009;58(11):2583–2587.

159. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. *N Engl J Med.* 2009;360(15):1509–1517.

160. Stefan N, Pfannenberg C, Haring HU. The importance of brown adipose tissue. *N Engl J Med.* 2009;361(4):416–417.

161. Carey A, Kingwell B. Brown adipose tissue in humans: therapeutic potential to combat obesity. *Pharmacol Ther.* 2013;140(1):26–33.

162. Cerneka H, Sand C, Michel MC. The odd sibling: features of β3 adrenoceptor pharmacology. *Mol Pharm.* 2014;86(5):479–484.

163. Arch JR, Trayhurn P. Detection of thermogenesis in rodents in response to antiobesity drugs and genetic modifications. *Front Physiol.* 2013;(4):64.